Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

The stock's fall snapped a three-day winning streak.

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Robinhood reported fourth-quarter revenue of $1.01 billion, up 115% year-over-year and a new company record. The revenue ...

Investors led by Elon Musk offer $97.4 billion for OpenAI. Sam Altman replies: 'No thank you.' ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

Piper Sandler raised the firm’s price target on Gilead (GILD) to $110 from $105 and keeps an Overweight rating on the shares after the company ...